Jay H. Hoofnagle et al., 2026-04-20: The US National Institutes of Health's LiverTox drug record for fenbendazole, last updated April 2026. It concludes that the drug is commonly associated with mild transient enzyme elevations and can cause clinically apparent acute liver injury, and assigns a likelihood score of C (probable cause).
Fenbendazole therapy is commonly associated with mild and transient serum enzyme elevations and can also lead to clinically apparent acute liver injury.
Jay H. Hoofnagle et al., 2026-04-20: The US National Institutes of Health's LiverTox drug record for fenbendazole, last updated April 2026. It concludes that the drug is commonly associated with mild transient enzyme elevations and can cause clinically apparent acute liver injury, and assigns a likelihood score of C (probable cause). Reference database entry (review), not a study; no subjects. United States (NIDDK/NIH). Funder: US government. Comparator: none. LiverTox's likelihood score C means 'probable cause of clinically apparent liver injury'; the record also notes that other benzimidazoles raise aminotransferases in up to 50% of patients treated for more than a few weeks. The page is a live database record dated 'Last Update: April 20, 2026'. It is filed as LINK because Bookshelf does not serve a stable per-record PDF. Also filed as FBA-59 (claims C3, F1).
